Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 10

1.

The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.

McKay RR, Bossé D, Xie W, Wankowicz SAM, Flaifel A, Brandao R, Lalani AA, Martini DJ, Wei XX, Braun DA, Van Allen E, Castellano D, De Velasco G, Wells JC, Heng DY, Fay AP, Schutz FA, Hsu J, Pal SK, Lee JL, Hsieh JJ, Harshman LC, Signoretti S, Motzer RJ, Feldman D, Choueiri TK.

Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.

PMID:
29748390
2.

Durable Clinical Benefit in Metastatic Renal Cell Carcinoma Patients Who Discontinue PD-1/PD-L1 Therapy for Immune-Related Adverse Events.

Martini DJ, Hamieh L, McKay RR, Harshman LC, Brandao R, Norton CK, Steinharter JA, Krajewski KM, Gao X, Schutz FA, McGregor B, Bossé D, Lalani AA, De Velasco G, Michaelson MD, McDermott DF, Choueiri TK.

Cancer Immunol Res. 2018 Apr;6(4):402-408. doi: 10.1158/2326-6066.CIR-17-0220. Epub 2018 Feb 1.

PMID:
29437040
3.

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma.

Lalani AA, Xie W, Martini DJ, Steinharter JA, Norton CK, Krajewski KM, Duquette A, Bossé D, Bellmunt J, Van Allen EM, McGregor BA, Creighton CJ, Harshman LC, Choueiri TK.

J Immunother Cancer. 2018 Jan 22;6(1):5. doi: 10.1186/s40425-018-0315-0.

4.

Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.

Miao D, Margolis CA, Gao W, Voss MH, Li W, Martini DJ, Norton C, Bossé D, Wankowicz SM, Cullen D, Horak C, Wind-Rotolo M, Tracy A, Giannakis M, Hodi FS, Drake CG, Ball MW, Allaf ME, Snyder A, Hellmann MD, Ho T, Motzer RJ, Signoretti S, Kaelin WG Jr, Choueiri TK, Van Allen EM.

Science. 2018 Feb 16;359(6377):801-806. doi: 10.1126/science.aan5951. Epub 2018 Jan 4.

5.

Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series.

Martini DJ, Lalani AA, Bossé D, Steinharter JA, Harshman LC, Hodi FS, Ott PA, Choueiri TK.

J Immunother Cancer. 2017 Aug 15;5(1):66. doi: 10.1186/s40425-017-0273-y.

6.

Classification and management of arthrofibrosis of the knee after anterior cruciate ligament reconstruction.

Shelbourne KD, Patel DV, Martini DJ.

Am J Sports Med. 1996 Nov-Dec;24(6):857-62.

PMID:
8947412
7.

Correlation of joint line tenderness and meniscal lesions in patients with acute anterior cruciate ligament tears.

Shelbourne KD, Martini DJ, McCarroll JR, VanMeter CD.

Am J Sports Med. 1995 Mar-Apr;23(2):166-9.

PMID:
7778700
8.

Diverticular abscesses: percutaneous drainage.

Neff CC, vanSonnenberg E, Casola G, Wittich GR, Hoyt DB, Halasz NA, Martini DJ.

Radiology. 1987 Apr;163(1):15-8.

PMID:
3823429
9.

Caudate lobe resection to reduce inferior vena caval hypertension prior to portacaval shunt.

Glotzer DJ, Martini DJ, Sacks BA.

Surgery. 1980 May;87(5):593-5.

PMID:
7368110
10.

Forty-two month follow-up of a semilunar valve homograft to the mitral area. Report of a case.

Coleman PG, Martini DJ, Resnekov L, Anagnostopoulos CE.

J Thorac Cardiovasc Surg. 1973 Jun;65(6):887-9. No abstract available.

PMID:
4574288

Supplemental Content

Loading ...
Support Center